Abstract
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Newlands, E., Rustin, G. & Brampton, M. Phase I trial of elactocin. Br J Cancer 74, 648–649 (1996). https://doi.org/10.1038/bjc.1996.415
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.415
This article is cited by
-
Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
BioDrugs (2022)
-
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
Journal of Experimental & Clinical Cancer Research (2021)
-
Therapeutic strategies targeting FOXO transcription factors
Nature Reviews Drug Discovery (2021)
-
Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity
Journal of Cancer Research and Clinical Oncology (2021)
-
Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors
BMC Cancer (2018)